Drug
Visugromab Rde
Visugromab Rde: highest development phase Phase 2, developed by CatalYm GmbH. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- CatalYm GmbH
Trials
| Drug | Phase | Indication |
|---|---|---|
| Visugromab RDE (recommended dose for expansion) NCT07219459 | Phase 2 | Unresectable or Metastatic Hepatocellular Carcinoma |
Latest
No recent events.
Follow Visugromab Rde on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.